Navigation Links
InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
Date:2/16/2011

BRISBANE, Calif., Feb. 16, 2011 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the fourth quarter and full year ended December 31, 2010.

InterMune reported net income for the fourth quarter of 2010 of $206.1 million, or $3.34 per diluted share, compared with a net loss of $28.6 million, or $0.62 per diluted share, in the fourth quarter of 2009. Net income for the full year 2010 was $122.4 million, or $2.13 per diluted share, compared with a net loss of $116.0 million, or $2.62 per diluted share, in 2009.

Results for the fourth quarter and full year 2010 include proceeds of $175.0 million from the sale of danoprevir in October 2010 and the accelerated recognition of approximately $57.3 million of remaining deferred revenue in connection with the termination of the 2006 Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. (Roche) collaboration agreement.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Our financial results in 2010 were driven by the sale of our rights to danoprevir to Roche, which enabled us to end the year with $295 million in cash and cash equivalents and provided the financial resources to independently maximize the world-wide value of pirfenidone. In December of 2010 we announced the adoption of a positive opinion by European regulatory authorities for the marketing authorization of Esbriet™ (pirfenidone) and we expect Esbriet to soon become the first therapy approved for the treatment of IPF patients in Europe. Regarding the U.S., we announced in January of 2011 our plan to conduct a Phase 3 study toward the potential U.S. FDA approval of Esbriet for the more than 100,000 Americans who suffer from IPF."

Recent Clinical Development, Business Highlights and Upcoming MilestonesEsbriet™ (pirfenidone):

  • InterMune reported on Dec
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
    2. InterMune Announces Start of Phase 1b Trial of ITMN-191
    3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
    4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
    5. InterMune Announces Progress on Pirfenidone in IPF
    6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
    7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
    8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
    9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
    10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
    11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... TARRYTOWN, N.Y. and BRIDGEWATER, N.J. ... Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and ... heart disease organizations to launch Cholesterol Counts , ... know about cholesterol, their numbers, and the risks associated ... to visit www. CholesterolCounts .com to take ...
    (Date:12/15/2014)... Texas , Dec. 15, 2014  Stephen Squires, ... manufacturer Quantum Materials Corp (OTCQB:QTMM), will be ... for Quantum Materials (RCQM) on December 16th, 2014. The ... of exotic nanomaterials in attracting top faculty and students ... to collaborate on research. "We have ...
    (Date:12/14/2014)... 2014  ChartSpan, a consumer platform for patients managing ... iPad medical app in the United States ... ChartSpan is an iPhone and iPad ... and send electronic healthcare records. The product was built ... of waiting for the healthcare system to deliver on ...
    Breaking Medicine Technology:Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3
    ... N.J., March 15, 2011 BD (Becton, Dickinson and ... led by its Nippon Becton Dickinson headquarters office in ... Fukushima prefecture.  The Company today confirmed that all of ... office in Tokyo is undamaged and functional. BD,s manufacturing ...
    ... 15, 2011 DJO Global, Inc. ("DJO" ... solutions for musculoskeletal health, vascular health and pain management, ... signed a definitive agreement to purchase Rikco International, LLC, ... $254.6 million in cash. The transaction is expected to ...
    Cached Medicine Technology:BD Statement Regarding Impact of Japan Earthquake 2DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort 2DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort 3DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort 4DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort 5
    (Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
    (Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
    (Date:12/17/2014)... Mozes HealthDay Reporter , TUESDAY, ... infectious diseases, one worrisome phenomenon is when an illness that ... -- known as zoonosis -- is not uncommon and keeps ... an animal-borne disease might make inroads into the human population. ... -- and the culprits in this case were guinea pigs. ...
    (Date:12/17/2014)... Amy Norton HealthDay Reporter ... has long been believed to improve overall health, but a ... help the heart, a new review finds. In fact, ... as brisk walking, said lead researcher Paula Chu, a doctoral ... The review, of 37 clinical trials, found that people randomly ...
    (Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s ... new study providing evidence on the impact of 100% ... , Sufficient enough evidence already exists showing a negative ... drinks, with the onset of tooth decay. One question ... as 100% fruit juice, meaning it is completely natural ...
    Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
    ... to severe malnutrition. In spite of hospitalization the survival rate ... Medicine had a research published concerning certain clinical signs that ... children who are at greater risk. ,The international group ... in Kenya, where 920 children were admitted with severe malnutrition ...
    ... evidence yet that a key portion of the traditional dose-response ... is wrong when it comes to measuring the effects of ... the University of Massachusetts Amherst. The findings, based on a ... yeast using 2,200 drugs, are published in the journal Toxicological ...
    ... Medical Center has for the first time identified several genes// ... solid human cancers – lung, breast, prostate and colon cancer. ... tumor suppressor genes, is often lost in tumor cells. This ... or through deletion of the gene. Loss of tumor suppression ...
    ... of major neck artery tears and stroke,// according to an ... of the American Academy of Neurology. ,“It appears ... study’s senior author Wengui Yu, MD, PhD, with the University ... American Academy of Neurology. ,The article reviewed the ...
    ... the evaluations published in PLoS Medicine, an innovative social ... strips to encourage gay and bisexual men in San ... an increase in syphilis tests. ,The cartoons ... posted on the streets, on bus shelters, on gay ...
    ... variant gene has been identified by researchers that help those ... seems to confer a preserving effect upon the mental faculties ... the Albert Einstein College of Medicine of Yeshiva University. December ... Nir Barzilai, the lead researcher is the director of the ...
    Cached Medicine News:Health News:New Study Challenges How Regulators Determine Risk 2Health News:Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers 2Health News:Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers 3Health News:You may Live Long and Think Clear With a Variant Gene 2
    Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
    Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
    Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
    Straight shafts with 7 mm tying platform. Flat serrated handle with dull titanium finish. Overall length 4.5 inches....
    Medicine Products: